The La protein is an essential RNA-binding protein implicated in different aspects of RNA metabolism. Herein, we report that small interfering (siRNA)-mediated La depletion reduces cell proliferation of different cell lines concomitant with a reduction in cyclin D1 (CCND1) protein. To exclude off-target effects we demonstrate that exogenous La expression in La-depleted cells restores cell proliferation and CCND1 protein levels. In contrast, proliferation of immortalized CCND1 knockout cells is not affected by La depletion, supporting a functional coherence between La, CCND1 and proliferation. Furthermore, we document by reversible in vivo crosslinking and ribonucleoprotein (RNP) immunoprecipitation an association of the La protein with CCND1 messengerRNA and that CCND1 internal ribosome entry site (IRES)-dependent translation is modulated by La protein level within the cell. In addition, we show elevated La protein expression in cervical cancer tissue and its correlation with aberrant CCND1 protein levels in cervical tumor tissue lysates. In conclusion, this study establishes a role of La in cell proliferation and CCND1 expression and demonstrates for the first time an overexpression of the RNA-binding protein La in solid tumors.
Introduction
The predominant nuclear mammalian La protein is an essential (Park et al., 2006) multifunctional RNAbinding protein involved in RNA processing (for reviews, see Maraia and Intine, 2002; Wolin and Cedervall, 2002) and translation (see below). Recent work suggests that the La protein is aberrantly regulated in different types of cancer. It has been shown that the La protein is elevated in BCR/ABL-transformed cells from patients with chronic myeloid leukemia (Trotta et al., 2003) . In this study, the authors report that the La protein promotes MDM2 protein expression through a translational mechanism. Recently, La protein expression has been shown to be increased in different types of tumor cell lines when compared with La protein levels of normal cells (Al-Ejeh et al., 2007) . Using murine glial cells, Brenet et al. (2009) demonstrated that green fluorescent protein (GFP)-tagged La protein shuttles in an serine-threonine protein kinase (AKT)-dependent manner to the cytoplasm, thereby supporting translation of a subset of messengerRNAs (mRNAs). The authors hypothesize that AKT-dependent shuttling of La to the cytoplasm might contribute to the well-known oncogenic effect of aberrant active AKT. Collectively, these studies suggest an important role of the RNA-binding protein La in cancer pathogenesis.
In addition to the well-described functions of the RNA-binding protein La in the processing of RNA polymerase III transcripts (for reviews, see Maraia, 2001; Wolin and Cedervall, 2002) , the mammalian La interacts with both cellular (McLaren et al., 1997; Brenet et al., 2005) and viral mRNAs (Spangberg et al., 2001; Ehlers et al., 2004) , and many reports suggest a role of La in regulation of cellular and viral translation. For instance, human La supports internal ribosome entry site (IRES)-and cap-dependent translation of viral mRNAs, such as hepatitis C virus, polio virus (Ali et al., 2000; Costa-Mattioli et al., 2004; Pudi et al., 2004) , HIV TAR mRNA (Svitkin et al., 1994; Chang et al., 1995) , suppresses translation of the hepatitis A virus (Cordes et al., 2008) , and regulates IRES-and cap-dependent translation of cellular mRNAs (for example, BiP mRNA , X-linked inhibitor of apoptosis protein (Holcik and Korneluk, 2000) , 5
0 TOP-mRNAs (Crosio et al., 2000) and Mdm2 mRNA (Trotta et al., 2003) ).
The primary objective of this study was to identify novel cellular functions of the La protein in cancerous cells. In our study, we show that the small interfering (siRNA)-mediated reduction of La protein in different cell lines correlates with both decrease in cell proliferation and downregulation of cyclin D1 (CCND1) protein.
Our evidence that CCND1 knockout cells proliferate in an La-independent manner and that La protein overexpression is accompanied by higher CCND1 protein levels in cervical cancer patient samples supports our hypothesis that the RNA-binding protein La contributes to cell proliferation and CCND1 expression in cancer.
Results
The La protein is required for cell proliferation Uncontrolled proliferation is a characteristic of most cancerous cells. To test whether La affects cell proliferation, we first reduced La protein by transfecting LasiRNAs into the cervical adenocarcinoma-derived HeLa cell line. After the second siRNA treatment, La protein depletion was stable over the whole observation period (24-96 h, Figure 1a ). Next, we measured the proliferation of La-depleted and control siRNA-treated cells over 4 days (Figure 1b) . The similar cell number in both groups 4-5 h after plating indicated that La depletion did not significantly affect cell re-attachment to culture dish (data not shown). However, cell proliferation rate was significantly reduced in La-depleted HeLa cells ( Figure 1c ) and calculation of doubling time of the cells revealed that control cells doubled faster (B18.2 h) compared with La-depleted cells (B39.5 h). To test whether La depletion induced apoptosis, we analyzed caspase 3-mediated cleavage of poly (ADP-ribose) polymerase (PARP) by western blotting and observed no increase in PARP cleavage (89 kDa, Figure 1d ), no increase in the number of dead cells by Annexin V and propidium iodide costaining after La depletion ( Figure 1e ) and no increase in the sub-G1 peak during fluorescence-activated cell sorting (FACS) analysis conducted at different time points after La depletion (data not shown). Furthermore, cell cycle analysis revealed no significant arrest of La-depleted cells in any cell cycle phase (Supplementary Figure 1) . We conclude that the reduced proliferation rate of La-depleted cancerous cells is not caused by enhanced cell death. Figure 1 The La protein is required for proliferation of HeLa cells. (a) Western blot analysis shows that La is efficiently depleted by La-specific siRNA over a period of 24-96 h after the second RNAi treatment. As control (con) cells were treated with luciferase-specific siRNAs. a-Tubulin protein was used as a loading control. (b) Cell proliferation of La-depleted (La siRNA) and control-treated (con siRNA) cells was measured over 4 days after the second RNAi treatment. Proliferation of La-depleted cells was reduced. (c) The proliferation rate (slope of growth curve) of three independent experiments was calculated and plotted. The proliferation rate of Ladepleted cells (La siRNA) was statistically significant reduced by about 75% when compared with control-treated cells (con siRNA) (P-value o0.05). (d) To test whether La-depletion induces programmed cell death, caspase-3 dependent cleavage of PARP was visualized with western blotting. The PARP-specific antibody recognizes a 116-kDa fragment and an 89-kDa apoptosis-related cleavage fragment. After La depletion, no difference in the amount of PARP cleavage products was observed indicating that caspase 3 pathways were not activated. GAPDH protein was used as a loading control. (e) To test whether the number of dead cells was different in La-depleted and control-treated cells Annexin V and propidium iodide co-staining was conducted on day 2 after the second siRNA treatment. Annexin V staining and propidium iodide incorporation was determined by FACS analysis. No increase in dead cells was determined after La depletion.
To test whether the phenotype observed in our experiments was evoked by the lack of La protein and not by La-siRNA off-target effects, we restored La protein to cells in which the endogenous La protein was depleted by siRNA treatment. For rescue experiments, we introduced three silent point mutations into the LasiRNA binding site of a GFP-La expression plasmid (GFP-La R ) from which a La-siRNA resistant GFP-La mRNA can be transcribed. We transfected La-depleted HeLa cells with GFP-La or GFP-La R and observed that GFP-La R expression functionally complemented endogenous La protein and restored cell proliferation (Supplementary Figure 2) . These data support the concept that La protein contributes to HeLa cell proliferation.
Human La is required for CCND1 expression To get insight into the overall effect on protein expression in La-depleted cells we applied 2-D-gel electrophoresis. About 6% of proteins are down regulated and less than 1% were up regulated in Ladepleted cells (Supplementary Figure 3) . As cell proliferation of La-depleted cells was reduced, we analyzed specifically the expression of proteins involved in cell proliferation by western blotting. In La-depleted HeLa cells, a significant reduction of the CCND1 was observed (Figure 2a) . In addition, we tested cyclin A, cyclin B, cyclin E, cyclin-dependent kinase 1, cyclindependent kinase 2 and p27, and saw that only protein levels of the cell cycle inhibitor, p21, were modestly reduced in La-depleted cells (Figure 2a) . We found that expression of Mdm2 and X-linked inhibitor of apoptosis protein was not affected by La depletion, which suggests that La-dependent translational regulation of those two proteins is specific to cell types and growth conditions (Figure 2a ).
This finding suggests that La depletion does not induce an overall reduction in protein expression, but affects the expression of specific proteins and prompted us to further investigate whether the reduction of CCND1 protein expression was specifically evoked by the lack of La protein. Therefore, we performed a rescue experiment demonstrating that expression of the GFPLa R plasmid in La-depleted HeLa cells restored CCND1 protein levels by 66% (Figure 2b , lane 2 vs lane 4). The experiment suggests that the La protein contributes to CCND1 expression.
To elucidate the mechanism by which La affects CCND1 expression, we compared CCND1 mRNA levels of control-treated with La-depleted HeLa cells by quantitative reverse transcriptase-PCR. No difference in CCND1 mRNA levels was observed (Figure 2c ). These data were confirmed by northern blot analysis (data not shown). Next, we compared the half-life of CCND1 protein in control-with that in La siRNAtreated cells and found that CCND1 half-life was not shorter in La-depleted cells compared with control cells (data not shown). These experiments suggest that La protein regulates CCND1 expression post-transcriptionally. Next, we were wondering whether we could recapitulate the defect in cell proliferation of La-depleted cells by a direct siRNA-mediated knockdown of CCND1 expression. FACS analysis of the cell cycle phases revealed that CCND1-depleted cells did not arrest in the G1 or any other cell cycle phase (Supplementary Figure 4) which, was analogous to our observations in La-depleted cells (Supplementary Figure 1) .
La associates with CCND1 mRNA
According to recent reports, La binds to cellular mRNAs and effects its translation (Trotta et al., 2003) . As La depletion reduces CCND1 without changing CCND1 mRNA level or protein half-life, we assumed that La interacts with CCND1 mRNA in living cells to regulate its expression. We prepared cell extracts from in vivo cross-linked HeLa cells to purify La mRNA complexes by immunoprecipitation ( Figure 3a ). After reverse cross-linking, RNA preparation and reverse transcriptase-PCR of the La-specific immunoprecipitated RNA, we conclude that CCND1 mRNA is specifically associated with La in living cells ( Figure 3b ). As specificity control, we show that abundant hetero nuclear ribonucleoprotein (hnRNP)-E2 mRNA was not immunoprecipitated with the La-specific antibody ( Figure 3b ). Next, we analyzed ongoing protein synthesis by 35-S methionine metabolic labeling of La-depleted and control-treated cells. The analysis of 35-S methionine protein lysates revealed that La depletion did not cause an overall reduction in protein synthesis (Supplementary Figure 5) . Those lysates were used for CCND1-and tubulin-specific immunoprecipitation. As shown in Figure 3c , tubulin protein was synthesized to similar degree in controltreated and La-depleted cells. However, CCND1 synthesis was massively reduced in La-depleted cells, suggesting that CCND1 translation was specifically hampered.
Several reports suggest a role of La in IRESdependent translation (Belsham et al., 1995; Ali et al., 2000; Holcik and Korneluk, 2000; Kim et al., 2001 ). Hence, we tested whether La regulates the CCND1 IRES element (Shi et al., 2005; Jo et al., 2008) . We transfected the dual luciferase reporter construct (pRCD1F, kind gift by Dr Gera in which the firefly luciferase expression is dependent on the CCND1 IRES element in La-depleted and control-treated cells) and analyzed luciferase expression 48 h later. As shown in Figure 3d , IRES-driven firefly luciferase expression was reduced by about 40% in La-depleted cells. Next we tested whether La overexpression stimulates the CCND1 IRES (Figure 3e ). In those experiments we cotransfected the CCND1 IRES reporter with GFP or GFP-La expression plasmids in HeLa cells and analyzed Figure 3 La protein is associated with CCND1 mRNA in living cells and regulates the CCND1 IRES element. To demonstrate an association between La and CCND1 mRNA, HeLa cells were cross-linked to fix potential La:RNA interactions in living cells. Cell lysates were prepared and used for La-specific IP. As control immunoglobulin isotype IgG 2a,k was applied (IgG con). After reversing the crosslink, RNA was prepared from starting material, La and control IP pellets (P). RNA was analyzed by RT-PCR using CCND1 and hetero nuclear ribonucleoprotein (hnRNP)-E2 specific primer. Figure 4) . The lysates were used for CCND1-and tubulin-specific IP. IP pellets were analyzed by SDS-polyacrylamide gel electrophoresis and autoradiography. CCND1 synthesis is strongly reduced in La-depleted cells when compared with control-treated cells. (d) The CCND1 IRES plasmid pRCD1F (Shi et al., 2005; Jo et al., 2008) were transfected into La-depleted and control-treated cells (in this experiments control siRNAs were a pool of random sequence obtained by Dharmacon, Lafayette, CO, USA) and Renilla and Firefly luciferase activity was determined using the Dual-Luciferase Reporter Assay (Promega). The Firefly and Renilla luciferase values were corrected by subtracting the backround luciferase values and the Firefly:Renilla luciferase ratio was calculated and plotted. Four independent transfections were analyzed. (e) The CCND1 IRES plasmid pRCD1F was co-transfected with GFP or GFP-La expression vectors. Cells were harvested 48 h later and luciferase expression was determined using the Dual-Luciferase Reporter Assay. The Firefly and Renilla luciferase values were corrected by subtracting the background luciferase values and the Firefly:Renilla luciferase ratio was calculated and plotted. Five independent transfections were analyzed. Overexpression of La is able to stimulate CCND1 IRES-dependent translation.
luciferase expression 48 h later. The calculation of the firefly:renilla luciferase ratio revealed that exogenous La protein is able to stimulate CCND1 IRES-dependent translation by almost three fold. These data demonstrate that La is associated with CCND1 mRNA in living cells and that La supports CCND1 IRESdependent translation.
La depletion effects proliferation and CCND1 expression in different types of cells Next we tested whether La protein contributes to cell proliferation of other types of cell lines. The proliferation rate of La-depleted prostate cancer cell line PC-3 ( Figure 4a ) and immortalized mouse embryonic fibroblasts (NIH-3T3) (Figure 4b ) was significantly reduced by about 50% (Figure 4c ). As shown for HeLa cells, an increase in cell death was not detected in La-depleted PC-3 cells by PARP analysis, Annexin V and propidium iodide co-staining (data not shown). Next we tested whether reduced proliferation rates were in coincident with low CCND1 expression in La-depleted PC-3 and NIH-3T3 cells, as shown for HeLa cells. Indeed La depletion caused a drop in CCND1 protein levels in all cell lines analyzed (Figure 4d ). These results suggest that the RNA-binding protein La is required for cell proliferation and CCND1 expression in different types of cells and is not restricted to a single cell line.
To support a functional link between La expression, CCND1 expression and cell proliferation, we compared the proliferation rate of La-depleted and control-treated immortalized mouse embryonic fibroblast (MEF) cells originating from CCND1 knockout mice (MEF CCND1À/À 3T3 cells (Albanese et al., 1999; Wang et al., 2003) ). In contrast to all other tested cell lines, the proliferation rate of La-depleted MEF CCND1À/À was not reduced (Figure 5a ). By quantitative western blot analysis we demonstrate that La protein expression was equally reduced in MEF CCND1À/À and NIH-3T3 control cells (Figure 5b ). These results support our notion that the La protein affects cell proliferation by a CCND1-mediated mechanism.
The La protein is overexpressed in cervical cancer Our studies indicate that RNA-binding protein La can regulate cell proliferation in different cancerous cell lines. To determine whether the La protein is aberrantly expressed in cancer tissue, we performed immunohistochemistry on cervical cancer tissue micro arrays (TMA) (TMA CR481, Biomax, Rockville, MD, USA) containing 12 cases of cervical squamous cell carcinoma (SCC) with 12 unmatched normal adjacent tissues, in a total of 24 patients for which 44 tissue cores were analyzed (duplicated cores). The TMA was hybridized with highly specific monoclonal La antibody (3B9) and counterstained with hematoxylin (Figures 6a, b, d and e) . As a control, hybridization with immunoglobulin isotype IgG 2a,k and counterstaining with hematoxylin were performed on a successive cut of the same TMA Figure 4 La depletion reduces cell proliferation and CCND1 expression in different cell lines. After La-depletion cell proliferation of (a) PC-3 and (b) NIH 3T3 cells were compared over 4 days after the second siRNA treatment. (c) The proliferation rate of PC-3 and NIH 3T3 cells were statistically significant reduced after La-depletion (P-value o0.05). Three independent experiments were analyzed. (d) Protein extracts from La-depleted (La) and control-treated (con) cells were analyzed by western blotting. In PC-3 and NIH 3T3 cells La depletion correlated with reduced CCND1 protein expression. GAPDH protein was used as a loading control. Chemiluminescence signals were recorded using an ImageQuant ECL systems and quantified using ImageQuant TL software. Scoring represents that 80% (score 4), 50% (score 3), 25% (score 2) or o10% (score 1) of nuclei are positive for La-specific staining.
La protein contributes to cell proliferation G Sommer et al (Figures 6c and f) . In SCC tissue, up to 80% of the cells had La-specific brown staining of the nucleus (Figures 6a and b) . Compared with cancerous tissue, less than 10% of the epithelial cells in adjacent normal cervical tissue (which often has chronically inflamed mucosa) were positive for nuclear La-specific staining (Figures 6d and e) . In addition, infiltrating cells within the cervical mucosa also stained positive for La (Figure 6e) . Two pathologists performed the scoring of the TMAs independently and the results were plotted as shown in Figure 6g . Our data show, for the first time, the expression of La in normal and cervical cancer tissue and establishes the significant overexpression of the RNA-binding protein La in cervical SCC tissue.
Elevated La expression correlates with elevated CCND1 expression in cervical cancer tissue lysates Our work suggests that the La protein is overexpressed in cervical cancer tissue and that it regulates CCND1 expression in different cell lines including cervical cancer HeLa cells. Therefore, we investigated whether La overexpression in cervical cancer tissue occurs coincidentally with an increase in CCND1 protein expression. We compared expression of La and CCND1 in tissue lysates by quantitative western blotting. We analyzed La and CCND1 expression in matched tissue lysates prepared from tumor and adjacent normal cervical tissue obtained from 12 patients (Figure 7) . After normalizing La and CCND1 protein against btubulin, we observed that of the 12 lysate sets, 7 tumor samples had above-normal La protein expression (Figure 7 , high La in tumor, n ¼ 7 sets) and 5 tumor samples had lower expression (Figure 7 , low La in tumor, n ¼ 5 sets). Interestingly, only in the seven tissue lysates with elevated La protein did we determine a strong increase in CCND1 protein levels. In contrast, CCND1 levels were normal in tissue lysates with low La protein. We conclude that our data support a model in which La protein regulates cell proliferation and contributes posttranscriptionally to enhanced CCND1 expression in different types of tumor cells.
Discussion
Here we present evidence that the cancer-associated RNA-binding protein La is required for cell proliferation and CCND1 expression in cancer. In summary, our data demonstrate the following: (I) La depletion causes a defect in cell proliferation of different types of cell lines (HeLa, PC-3, NIH-3T3); (II) La depletion led to a decrease in CCND1 protein levels in different cell types, which can be restored by exogenouse-La expression; (III) La is associated with CCND1 mRNA in living cells and activates CCND1-IRES; (IV) La protein is overexpressed in cervical cancer tissue; and (V) elevated La levels are paralleled by increased CCND1 protein in cervical tissue lysates.
Recently, a role was suggested for the RNA-binding protein La in tumorigenesis: La protein is overexpressed in chronic myeloid leukemia cells and stimulates the expression of Mdm2 (Trotta et al., 2003) , a negative regulator of the tumor suppressor p53. Brenet et al. (2009) reported recently that in murine glial cells, the GFP-tagged La protein is relocated to the cytoplasm after phosphorylation by protein kinase AKT. Furthermore, Brenet et al. (2009) provided evidence that the assortment of translational active La-associated mRNAs changes upon AKT activation, suggesting that La might contribute on the translational level to the oncogenic effect of aberrant AKT activity in cancerous cells. A recent report suggests that the La protein is elevated in numerous cancer cell lines (Al-Ejeh et al., 2007) , but so far evidence is lacking to demonstrate that the La protein is overexpressed in solid tumor tissue. The highly significant overexpression of La in cervical cancer (Figure 6 ), in chronic myeloid leukemia (Trotta et al., 2003) , and the AKT-dependent phosphorylation of the RNA-binding protein La (Brenet et al., 2009) might be a characteristic of various cancerous cells and it is tempting to speculate that the La protein supports tumorigenesis when aberrantly expressed.
Our attempt to illuminate cellular processes regulated by the La protein revealed that cell proliferation of the human cervical (HeLa) and prostate (PC-3) cancer cell lines, and murine immortalized embryonic fibroblasts (NIH 3T3) is La-dependent (Figure 1 and 4) . However, the finding that proliferation of La-depleted MEF CCND1À/À was not reduced (Figure 5a ) suggests that CCND1 might mediate the effect of La on cell proliferation. Ladependent expression of the cell cycle regulatory protein CCND1 in different cell lines (Figure 2a and 4d) , the CCND1 rescue experiments (Figure 2b) , the La dependent regulation of the CCND1 IRES element (Figures 3d and e) and the finding that elevated La expression in cervical cancer tissue lysates strongly correlates with elevated CCND1 levels (Figure 7) are further supportive for a model in which La contributes to cell proliferation and CCND1 translation. CCND1 expression is upregulated in response to mitogens and associates with cyclin-dependent kinases 4 or 6 (CDK4/ 6) (Motokura et al., 1991; Fu et al., 2004; Knudsen et al., 2006; Musgrove, 2006) . The CCND1/CDK4/6 complex leads to phosphorylation of the retinoblastoma protein, which normally exists in a hypophosphorylated form associated with the transcription factor E2F. Upon CCND1/CDK4/6-dependent phosphorylation, retinoblastoma protein releases the transcription factor E2F. Subsequently, E2F activates a number of genes initiating the transition from the G1 into the S phase. Importantly, the cell cycle regulator CCND1 is aberrantly expressed in different cancers (for review, see Diehl, 2002; Fu et al., 2004) . However, often in the cervical cancer tissue and in the HeLa cervical cancer cell line, CCND1/CDK4/6-dependent regulation is nullified by the action of the human papilloma virus protein E7 (Chellappan et al., 1992; McLaughlinDrubin and Munger, 2009) . Hence, it is assumed that cell proliferation in papilloma virus-infected cervical cancer tissue/cells is mainly CCND1-independent and contradicts our notion that La regulates cell proliferation through a CCND1-mediated mechanism. However, CCND1 might contribute to cell proliferation by another mechanism. It is well established that CCND1 fulfills CDK-independent functions and that CCND1 regulates a number of transcription factors or transcriptional regulatory proteins (for review, see Fu et al., 2004) . It is important to note that a comprehensive analysis of gene expression data suggests that CCND1 counteracts the transcription factor C/EBPb (Lamb et al., 2003) , which regulates cell differentiation and cell proliferation (for review, see Nerlov, 2007; Zahnow, 2009) . C/EBPb is translated into two different isoforms: LAP (C/EBPb, p44, p42) and LIP (p20) (Calkhoven et al., 2000; Zahnow, 2009 ). The LAP:LIP ratio is assumed to regulate cell proliferation through the LAPmediated repression of E2F target genes (Sebastian et al., 2005) . Lamb et al. (2003) suggested that CCND1 acts similar to LIP by counteracting LAP (C/EBPbeta) functions. Hence, it is reasonable to speculate that La-dependent CCND1 expression is an important mechanism which contributes to cell proliferation even in human papilloma virus-infected cells. However, we also have to assume that additional factors-for example not yet identified La-regulated proteins (Supplementary Figure 3) -in concert with CCND1 are required for La to contribute to cell proliferation in different cell types.
Interestingly, in cervical tumor lysates elevated La protein levels are observed along with an increase in CCND1 protein levels (Figure 7) . The finding that CCND1 protein is elevated in those lysates is in agreement with recent studies demonstrating elevated CCND1 expression in cervical cancer (Nichols et al., 1996; Cheung et al., 2001; Carreras et al., 2007; Conesa-Zamora et al., 2009) . Although, in one study, CCND1 expression was reduced in most of the analyzed samples, CCND1 was elevated in invasive cancer and it correlates with lower overall survival (Bae et al., 2001) . Importantly, overexpression of CCND1 was not thought to be due to gene amplification, suggesting posttranscriptional mechanism in stimulating CCND1 expression (Muise-Helmericks et al., 1998; Cheung et al., 2001; Shi et al., 2005; Inge et al., 2008; Frost et al., 2009; Cowling, 2010) .
It has been shown that the La protein regulates translation of Mdm2 (Trotta et al., 2003) and IRESdependent translation of the X-linked inhibitor of apoptosis (Holcik and Korneluk, 2000) . Upregulation of both proteins is expected to support cancer development by repressing the expression of the tumor suppressor p53 and blocking apoptosis, respectively. In this study we found for the first time that La contributes to the expression of the cooperative oncogene CCND1 most likely by regulating CCND1 IRES-dependent mRNA translation (Figure 3) . The CCND1 IRES element was intensively studied in the past (Shi et al., 2005; Jo et al., 2008) . It will be interesting to dissect the molecular details of La-dependent regulation of CCND1 IRES in the future and the cellular conditions allowing La to activate the CCND1 IRES. As an example, a change not only in total La protein levels, as shown in this study, but also a redistribution to the cytoplasm (Brenet et al., 2009 ) might contribute to the ability of La to stimulate translation of specific mRNAs in cancerous cells.
Our future work will focus on the dissection of the molecular mechanism of La-dependent CCND1 regulation and cellular condition allowing La to stimulate CCND1 translation. Our study clearly demonstrates that La regulates the expression of CCND1 and cell proliferation in different cell lines, suggesting a model in which the La protein has an important role in cancer pathology.
Materials and methods

Oligonucleotides
Please see Supplementary Materials.
DNA plasmids and mutagenesis GFP-La R was prepared by introducing three silent point mutations in the La siRNA binding site of a GFP-La plasmid by PCR-based mutagenesis using oligonucleotides La-M48S and La-M49AS. PCR products were digested with DpnI and subsequently ligated using the Rapid Ligation Kit (Roche, Germany) following the manufacturer's instructions. Plasmids were sequenced to confirm mutagenesis.
Cell culture and transfections
HeLa cells were purchased from ATCC, expanded and aliquots were stored in liquid nitrogen. New HeLa cell cultures were established every 2-3 months. MEF CCND1À/À 3T3 cells (Albanese et al., 1999; Wang et al., 2003) were kindly provided by RG Pestell (Thomas Jefferson University, Philadelphia, PA, USA). All cells were cultured in complete DMEM plus 10% fetal bovine serum. For siRNA treatment, 0.5 Â 10 5 HeLa cells were plated per well (12-well plate). At 2 h before transfection, complete DMEM was replaced by OPTI-MEM (Invitrogen, Carlsbad, CA, USA) and siRNAs (final concentration 100 nM) were transfected using Oligofectamine (Invitrogen). For the second siRNA treatment, cells were replated on day 5 after the first treatment and again transfected with siRNA the following day as described. For siRNA treatment of MEF CCND1À/À and NIH 3T3 cells 1.0-2.0 Â 10 6 cells were transfected with 3 mg of La-specific or con-siRNA using a nucleofector according to the manufacturer's instructions (AMAXA, Cologne, Germany, program A-023). For the second siRNA treatment, cells were transfected on day 5 after first treatment as described. Transfections of plasmid DNA were performed using Fugene-6 reagent (Roche, Indianapolis, IN, USA) according to the manufacturer's instructions.
Proliferation assays, rescue experiments, FACS analysis and Annexin V staining For cell proliferation, the CyQuant Cell proliferation Assay Kit (Invitrogen) was applied according to the manufacturer's instructions. At 2 days after the second siRNA treatment 4000 HeLa cells, 1250 MEFs CCND1À/À cells, 5000 PC-3 cells or 1000 NIH 3T3 cells per well were plated in 96-well plates. Re-plating efficiency was determined 4-5 h after plating and cell proliferation was measured daily for 4 days.
For rescue experiments La-depleted and control-treated cells were replated in 12 wells on day 2 after the first siRNA treatment. GFP-La or GFP-La R plasmid DNA was transfected on day 3 or 4. The next day, cells were sorted for GFP signals with an Aria FACS cell sorter (BD Biosciences, San Jose, CA, USA), and positive cells were cultured and replated one day before the second siRNA treatment. For endpoint analysis, on day 1 after the second treatment 0.25 Â 10 5 cells were transferred to 10-cm culture dishes and cultured for 3-4 days. Cells were stained with GIEMSA staining solution (Merck, Whitehouse Station, NJ, USA) and counted. From the same experiments, additional cells were harvested 48 h after the second RNAi to analyze CCND1 protein expression in GFP-La and GFP-La R -expressing cells. Protein lysates were prepared and analyzed for CCND1 by western blotting.
A number of dead cells were determined with the Annexin-V-FLUOS Staining Kit (Roche) according to the manufacturer's instructions. FACS analysis was performed according to standard protocols at the Flow Cytometry and Cell Sorting facility (MUSC, Charleston, SC, USA). Caspase-3 dependent processing of PARP was determined by western blot analysis.
Western blot analysis
Cells were lysed in cell lysis buffer (10 mM Tris, 10 mM KCl, 10 mM MgCl 2 , 0.2% Nonidet-P40, 1 mM EDTA, 420 mM NaCl, 1% protease inhibitor) and protein was analyzed by SDSpolyacrylamide gel electrophoresis (PAGE). The antibodies used and their dilutions are described under Supplementary Materials. Secondary antibodies (1:20 000) were horseradish peroxidase-conjugated (Dianova, Hamburg, Germany). Quantification was performed with an ImageQuant RT ECL instrument and ImageQuant TL software (GE Healthcare, Piscataway, NJ, USA).
In vivo crosslinking and immunoprecipitation
For reversible in vivo crosslinking we followed the protocol (Niranjanakumari et al., 2002) with modifications (G Dreyfuss, personal communication, University of Pennsylvania School of Medicine) mentioned below. For formaldehyde fixation the 1-2 Â 10 6 trypsinized cells were washed twice with ice cold 1 Â PBS, resuspended in 1 Â PBS containing 0.2% (v/v) formaldehyde (Thermo Scientific, Pittsburgh, PA, USA, Methanol-free) and incubated at room temperature for 10 min with slow mixing. The reaction was quenched by adding glycine (pH 7.0) to a final concentration of 0.25 M followed by incubation at room temperature for 10 min with slow mixing.
For immunoprecipitation of La-associated RNA, cells were harvested and lysed in ice-cold lysis buffer containing 20 mM Tris-HCl pH 7.4, 150 mM NaCl, 1 mM EDTA, 10% glycerol, 1% NP-40, 1 Â Proteinease Inhibitor Mix (Roche), 50 mM NaF, 1 mM Na 3 VO 4 , 1 mM DTT and 20 U rRNAsin (Promega, Madison, WI, USA). The cell extract was sonicated and clarified by centrifugation at 4 1C for 10 min. Cell extracts were pre-cleared by incubation with Protein A-Sepharose (GE Healthcare) in the presence of 20 U rRNAsin at 4 1C for 2 h followed by immunoprecipitation at 4 1C over night in presence of Protein A-Sepharose (GE Healthcare), 20 U rRNAsin and 2.5 mg of the following antibodies: mouse monoclonal anti-La 3B9 (a kind gift from M Bachmann, Technical University Dresden, Dresden, Germany) or purified mouse immunoglobulin isotype IgG 2a,k (eBioscience, San Diego, CA, USA).
For CCND1 and tubulin immunoprecipitation from 35 Smethionine metabolic labeled protein lysates (Supplementary Figure 5 ) the above protocol was used and monoclonal anti-CCND1 and anti-a-tubulin were applied.
Total RNA isolation and quantitative RT-PCR Total RNA was isolated using TriPure (Roche) following the manufacturer's instructions. Reverse transcription of RNA was performed using the ThermoScript RT-PCR System (Invitrogen). Quantitative PCR amplification was performed on the BioRad iCycler-iQ system (BioRad, Hercules, CA, USA) using the iQ-SYBR Green Supermix (BioRad).
Immunohistochemical staining
The cervical cancer TMAs with normal adjacent tissues (TMA CR481) were purchased from Biomax. Staining was performed according to standard protocols. Briefly, slides were baked for 2 h at 60 1C, deparaffinized in xylene, and stepwise rehydrated in ethanol (100-50%) followed by ddH 2 O and 1 Â PBS washes. Slides were boiled for 10 min in citrate-based antigen unmasking solution (Vector), washed with 1 Â PBS, treated with 0.3% solution of H 2 O 2 in ddH 2 O for 20 min and washed in 1 Â PBS. Slides were blocked with horse serum, incubated with Laspecific antibody (1:200 dilution in horse serum), or mouse isotype IgG 2a,k (eBioscience) at 4 1C overnight. Staining was completed using ImmPress Reagent, anti-Mouse Ig Peroxidase, and ImmPACT DAB substrate (Vector). Tissue sections were counterstained with Hematoxylin QS Nuclear Counterstain (Modifies Mayer's Formula, Vector).
Cervical cancer tissue lysates
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